Abstract-Arterial generalized transfer functions (GTFs)
C hronic kidney disease (CKD) is a common problem, with Ͼ10% of the general population estimated to have a marker of renal disease. 1 Cardiovascular disease is a common complication, and renal dysfunction is regarded as an independent risk factor for adverse cardiovascular events. 2 Renal disease affects the nature of arterial pulse wave propagation through the vascular tree, because of increases in arterial stiffening, 3 changes in the microcirculation (eg, microvascular calcification 4 ), and impaired endotheliumdependent vasodilatation. 5 These vascular changes lead to increased augmentation of central systolic blood pressure (BP), placing greater pulsatile stress on the aorta, increasing left ventricular afterload and myocardial oxygen consumption, 6 and compromising myocardial perfusion during diastole. 7 The subsequent structural changes, remodeling, and atherogenesis 8 may explain the increased incidence of vascular events in this population. Indeed, measures of arterial stiffness and the central arterial pressure contour have been associated with cardiovascular complications in a number of patient groups 9 and, in particular, have been shown to predict mortality in patients with end-stage renal disease. 10 To avoid the need for invasive measurement of central pressure, an arterial transfer function can be used to estimate the central pressure waveform from noninvasive peripheral measurements. A transfer function is a mathematical description of the change in gain and phase of different frequency components of a pulsatile signal between 2 measurement sites. Generalized transfer functions (GTFs) assume that the arterial properties between the 2 sites are constant in all individuals. Radial-toaortic GTFs are increasingly used to estimate central hemodynamic measures and have indeed been used to show that that aortic augmentation index (AIx) is increased in association with severity of coronary disease in CKD 11 and the presence of kidney disease in normotensive subjects with normal renal function. 12 The most frequently used GTF is that used by the SphygmoCor device (AtCor Medical), which was validated in a population with coronary heart disease, 13 but no validation work has been carried out in patients with CKD. The aim of the current study was to use carotid waveforms as surrogates of central measurements to examine whether changes in vascular function, which occur in patients with CKD, might result in changes to the peripheral-to-central GTF or in errors in the degree of estimation of central hemodynamic values.
Methods

Subjects
Male and female subjects, aged 18 to 65 years, with CKD were recruited from local hospital renal unit databases. Community subjects with normal renal function, but matched for age, sex, and BP, were used as controls. Subjects were excluded if there was a history of diabetes mellitus, major cardiac or peripheral vascular disease, systemic vasculitis or connective tissue disease, neurological or respiratory disease, alcohol misuse, pregnancy, BP Ͼ160/ 100 mm Hg, or if they were on dialysis. Medications were not stopped before the study, but patients on nitrates were excluded. Studies were approved by the local research ethics committee and conformed to the principles of the Declaration of Helsinki. Volunteers provided written informed consent.
CKD Staging
Stages of CKD were defined by the Kidney Disease Outcomes Quality Initiative. 14 Serum creatinine was measured to determine glomerular filtration rate (GFR) using the Cockcroft-Gault equation corrected for body surface area. 15 CKD was defined as either kidney damage or a GFR Յ60 mL/min per 1.73 m 2 for Ն3 months. Kidney damage was defined as either pathological abnormalities or markers of damage, including abnormalities in blood or urine tests, or imaging studies. Cutoff values of GFR for stages 1 to 5, respectively, were Ն90, 60 to 89, 30 to 59, 15 to 29, and Ͻ15 mL/min per 1.73 m 2 . Subjects in stages 4 and 5 were subsequently combined because of small numbers in the latter group.
Study Protocol
Subjects were studied in a quiet, temperature controlled environment after 30 minutes of supine rest. They were asked to refrain from caffeine, food, and smoking for 12 hours and alcohol for 24 hours before the study. Subjects were also asked to withhold their medications on the morning of the study. BP was measured at the brachial artery using a validated Omron HEM-705CP device. Carotidfemoral pulse wave velocity (PWV) was measured using the SphygmoCor system. Simultaneous noninvasive carotid and radial artery waveforms were recorded using hand-held (SPT301, Millar Instruments) and automated (CBM7000, Colin Medical) tonometers, respectively. Radial waveforms were calibrated to brachial systolic and diastolic pressures. Carotid waveforms were calibrated to diastolic and radial mean pressures. Signals were digitized at 200 Hz using a MacLab 400 analog-digital converter (ADInstruments) and stored for offline analysis.
Waveform Analysis
Signals were analyzed using custom software written in LabVIEW 6.1 (National Instruments). Ten-second simultaneous radial and carotid waveforms were analyzed. Signals were upsampled to 1 kHz using cubic spline interpolation and synchronized at the wave foot using the intersecting tangent to remove the phase shift introduced by the transit time between the 2 signals. This also enabled calculation of carotid-radial PWV. Transfer functions were computed from the 2 waveforms for each subject by dividing the Fourier transform of the input (radial) signal by that of the output (carotid) signal. GTFs were computed for each of the 5 study groups (controls and stages 1, 2, 3, and 4/5) by averaging the relevant transfer functions Ͼ0 to 10 Hz. A further radial-to-carotid GTF was computed based on resting pulse wave data obtained independently during a study of young healthy volunteers. 16 This GTF was then applied to the recorded radial waveforms to generate derived carotid waveforms. Waveforms were analyzed in the time domain by ensemble averaging to give a wave representative of a single cardiac cycle. Waveform parameters calculated were AIx (expressed as difference in amplitude between incident and reflected waves as a percentage of pulse pressure), maximum wave slope, ejection duration (determined from wave foot to dicrotic notch), and delay between incident and reflected waves (the T1 to T2 delay). Inflection points on the waveform were identified using a computer algorithm, by finding the relevant zero-crossing points on the second and third derivatives of the waveform, with derivatives smoothed using a 5-iteration 25-point centered moving average.
Statistical Analysis
Data were analyzed using SPSS version 14.0 (SPSS Inc). Results are expressed as meanϮSD, with differences between actual and derived carotid values expressed as mean differenceϮSE. Actual and derived waveforms were also compared by root-mean-square error (RMSE). GTFs were analyzed by examining the frequencies at which peak change in magnitude and phase occurred and the area under the curves (AUCs) for both gain and phase for frequencies between 0 and 10 Hz. One-way ANOVA was used to examine differences between subject groups (Kruskal-Wallis test for nonparametric data). Linear regression was used to examine correlations between GFR and different measures, with additional stepwise multivariate models to correct for drug use, age, sex, body mass index, smoking, and lipid profile.
Results
Ninety-four subjects were studied, and characteristics are shown in Table 1 . Persons with higher CKD staging were older (Pϭ0.002, ANOVA) and took more cardiovascular drugs (PϽ0.05 for all agents except ␤-blockers). Measured hemodynamic values are shown in Table 2 . There were significant inverse correlations between GFR and systolic (both radial and carotid), diastolic, and mean BP; carotid (but not radial) AIx; ejection period; and carotid-femoral PWV. Heart rate was positively associated with GFR. The T1 to T2 delay, maximum wave slope, and carotid-radial PWV were not correlated with GFR.
Mean bias between measured and derived carotid waveform parameters are given in Table 3 , with Bland-Altman plots for these parameters shown in Figure 1 . Over the entire study population, there were no significant differences in derived carotid values compared with measured values for systolic BP (Pϭ0.13), AIx (Pϭ0.30), maximum wave slope (Pϭ0.36), and the T1 to T2 delay (Pϭ0.57). Derived pulse pressure was slightly lower (Ϫ0.8 mm Hg), but this did not reach statistical significance (Pϭ0.06). The ejection period was underestimated (Ϫ4.4Ϯ9.0 ms; PϽ0.001). No significant relationship was found between the degree of bias of any derived waveform parameter and GFR or CKD stage. This lack of correlation persisted after correction for drug use and also after further correction for additional cardiovascular risk factors. The RMSE was relatively small between actual and derived carotid waves and increased slightly with worsening GFR (RϭϪ0.22; BϭϪ0.007; Pϭ0.035), although this relationship was not observed when RMSE was compared against CKD stage (Pϭ0.50 by ANOVA). This relationship between GFR and RMSE persisted after correction for drug use and after further correction for other confounding factors (PϽ0.05). Of note, angiotensinconverting enzyme inhibitor and angiotensin receptor blocker use was positively correlated (independent of GFR, age, and sex) with the error in pulse pressure, systolic pressure, and ejection duration (Bϭ1.7, 2.2, and 3.9, respectively; PϽ0.05) and negatively correlated with RMSE (BϭϪ0.65; Pϭ0.01). Calcium channel blocker use was negatively correlated with error in systolic pressure (BϭϪ1.9; Pϭ0.035). Only the correlation between drugs and RMSE and systolic pressure error persisted after further correction for additional confounding factors.
Mean transfer functions calculated for the 5 subject groups are shown in Figure 2 . Across all of the subjects, the average AUC for gain (0 to 10 Hz) was 3.9Ϯ0.8 Hz (meanϮSD), and the minimum gain was 0.52Ϯ0.13 occurring at 4.3Ϯ1.5 Hz. There were no significant differences observed between CKD groups in terms of AUC (Pϭ0.40) or the magnitude (Pϭ0.46) or frequency (Pϭ0.12) of minimum gain. The AUC for phase was Ϫ0.16Ϯ0.72 radians Hz, with a maximum phase shift of Ϫ0.46Ϯ0.20 radians occurring at 2.8Ϯ1.5 Hz (mean for all subjects). Slight differences were observed among the 5 stages, although these did not reach statistical significance (AUC, Pϭ0.057; magnitude of maximum phase shift, Pϭ0.071; frequency of maximum phase shift, Pϭ0.12). Post hoc analysis, however, revealed that there was a tendency for the AUC to be more negative and the peak phase shift to be greater for stage 4/5 compared with every other CKD stage (excluding controls, PϽ0.05 and PϽ0.02, respectively, Student t test), although the frequency at which the peak phase shift occurred did not vary (Pϭ0.32).
Discussion
This study shows for the first time that the peripheral-tocentral arterial transfer function remains relatively stable in subjects with varying degrees of CKD and that an indepen- Values are mean (SD) or n (%). GFR is corrected for BSA. P is significant difference between stages, calculated by 1-way ANOVA (Kruskal-Wallis test for male and drugs). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; BMI, body mass index. 13, [23] [24] [25] However, the invasive nature of these validation studies limits them to individuals undergoing clinically indicated cardiac catheterization and is not suited to examining the transfer function in at-risk subjects in whom such investigations are not justified. Differences have been described previously in the peripheral-to-central transfer function between men and women, 26 diabetic and nondiabetic populations, 27 individuals with and without coronary disease, 28 and before and after exercise, 16 and the effects of CKD on vascular function might, therefore, be expected to also impact on the transfer function in this population. There is no single agreed method of validation, and so we have attempted to study the effect of renal function on a range of factors, both in the time domain and frequency domain.
Central arterial stiffness has indeed been shown by others to change with CKD stage. 29 This was confirmed by the present study, and significant changes in pressure augmentation were also observed. Why should the transfer function be relatively constant in the population studied, particularly given the observed effect of CKD stage on various hemodynamic measures? The transfer function is influenced by a number of factors, including the presence of vascular calcification or atheroma, the elastic properties of the vessels, and arterial path length. Vascular disease, however, is present to a lesser degree in the upper limb compared with elsewhere in the arterial system and can, therefore, be expected to have minimal impact on the transfer function. Furthermore, changes in the arterial wall elastic properties tend to affect higher frequency wave components, again with less bearing on the transfer function. We attempted to minimize variations in age and BP, to reduce confounding effects on arterial stiffness, and, therefore, avoided masking any potential effect on the GTF of differences in underlying intrinsic arterial wall properties attributed solely to renal dysfunction. This is supported by the relative constancy of conduit artery PWV across CKD stages, despite the negative correlation between central PWV and GFR. We also excluded patients with diabetes mellitus to enable us to specifically examine the effect of CKD by removing an additional important confounding factor. The lack of diabetes mellitus and relatively young age may also explain why the central PWV was lower than might otherwise have been expected. Finally, the arm length is relatively constant between individuals. Although synchronizing carotid and radial signals removes the variability in phase shift introduced by the true pulse wave transit time between the 2 sites, it does not take into account variation in the apparent phase velocities of differing harmonic components. Nonetheless, the constancy of arm length means that variation in apparent phase velocity of different frequency components has relatively little effect on the transfer function. It is perhaps worth noting that post hoc analysis suggested that the stage 4/5 GTF differed slightly in terms of maximum phase shift, perhaps reflecting altered biomechanical properties of the vessel wall in this population, although this did not translate to significant differences in the shape of the derived pulse wave. Unfortunately, the lack of patients in stage 5 necessitated combining the analysis with stage 4, thus potentially masking differences in the transfer function in the more severe cases of renal impairment.
Previous studies have found little effect of drugs on the GTF 13, [23] [24] [25] ; this is supported by the present study, which found significant but nonetheless only small changes in derived waveform parameters in the presence of drugs. Individuals with worse renal function were taking more cardiovascular medication. It is, therefore, difficult to be sure that the therapeutic effect of these agents does not reverse any effect on the transfer function of the underlying vascular dysfunction resulting from renal disease. However, this supposition is not supported by our multivariate analyses. Regardless, the differences in drug use reflect those expected in this population, and the use of a GTF in normal clinical circumstances could, therefore, still be justified.
Although we found no clear effect of renal function on the relationship between radial and carotid arteries, it is possible that the radial-to-renal (or indeed carotid-to-renal) artery transfer function may be affected. Furthermore, noninvasive estimation of the renal (rather than proximal aortic) waveform could be of prognostic value. Our study is obviously unable to answer these questions. Recent work by Temmar et al 30 did not find a correlation between plasma creatinine and the pulse pressure amplification between the proximal aorta and the aorta at the level of the renal arteries. Assuming that this finding also implies that the proximal-to-distal aortic transfer function is unaffected by plasma creatinine, when taken with our own findings it can be inferred that renal function is unlikely to significantly alter the transfer function between a peripheral vessel (eg, radial) and the renal artery. However, invasive studies of the renal artery itself will be required to resolve this question fully.
Compared with radial artery measurements, carotid waveform acquisition can be technically more challenging because of factors such as obesity and respiration and is not easily automated. Peripheral measurements may, therefore, be preferred. However, the purpose of the study was not the prediction of carotid waveforms, per se, but the use of carotid waveforms as a surrogate for central measurement to permit the examination of variations in transfer function between subjects in whom invasive aortic measurements are not possible. It is not possible to say with certainty, however, that constancy in the radial-carotid transfer function will necessarily translate to consistency in the radial-aortic transfer function. Nonetheless, the carotid waveform has been used previously as an alternative to invasive aortic measurements. 10, 17 Indeed, differences among systolic pressure, 31 pressure augmentation, 8 and arterial stiffness 32 are relatively small between the aortic and carotid sites. This certainly lends weight to the argument that the present findings might be extended to estimation of aortic waves.
Perspectives
The present work supports the argument that a single peripheral-to-central GTF can be used with equivalence in patients with varying degrees of CKD. Further work is still required to evaluate what role central waveforms derived using GTFs have in the management of this patient population. Importantly, the approach used in the present study could also be applied to other areas where the validity of GTFs might be called into question.
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